Impact of antibiotic prophylaxis in second-stage surgery in joint prosthesis infection treated with two-stage

Jose M Barbero Allende1,2, Encarnación Fernández Antón3,4, Joan Gómez-Junyent5,6,7

  • 1Internal Medicine Department, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain. j_m_barbero@yahoo.es.

Abstract

Insights

Antibiotic prophylaxis after prosthetic joint infection (PJI) surgery is not standardized. Regimens targeting methicillin-resistant staphylococci and Pseudomonas significantly reduce the risk of reinfection (RePJI).

Area of Science:

  • Orthopedic surgery
  • Infectious diseases
  • Pharmacology

Background:

  • Prosthetic joint infection (PJI) treatment involves two-stage exchange, with a high risk of reinfection (RePJI).
  • Evidence for optimal antibiotic prophylaxis in second-stage surgery is limited.
  • This study aimed to describe current prophylaxis practices and their impact on RePJI risk.

Purpose of the Study:

  • To document antibiotic prophylaxis regimens used in second-stage prosthetic joint replacement surgery.
  • To evaluate the effectiveness of different prophylaxis strategies in preventing reinfection.

Main Methods:

  • Retrospective, multicenter case-control study in Spanish hospitals.
  • Included cases of PJI treated with two-stage exchange and subsequent RePJI.
  • Matched controls were selected, and prophylaxis regimens were analyzed based on antibacterial spectrum using conditional logistic regression.

Main Results:

  • 90 cases and 172 controls were analyzed; Staphylococcus epidermidis and Pseudomonas aeruginosa were common pathogens.
  • A wide variety of 83 prophylaxis regimens were used, with no single regimen dominating.
  • Regimens including antibiotics active against methicillin-resistant staphylococci and Pseudomonas spp. were associated with a significantly lower risk of RePJI (adjusted OR = 0.24).

Conclusions:

  • Significant diversity exists in antibiotic prophylaxis regimens for second-stage exchange surgery.
  • Prophylaxis should incorporate agents effective against both methicillin-resistant staphylococci and Pseudomonas to minimize RePJI risk.